KPV is the three-amino-acid tail of alpha-MSH, a natural human signalling hormone \u2014 and those three residues carry the parent molecule’s anti-inflammatory action in a package small enough to study everywhere from gut tissue to skin.<\/p>\n
Alpha-MSH is a melanocortin hormone with documented anti-inflammatory signalling. Researchers isolated its three terminal amino acids \u2014 lysine, proline, valine \u2014 and found the fragment retains the anti-inflammatory activity without the pigmentation signalling of the parent hormone. That separation is what makes KPV its own research subject.<\/p>\n
The KPV literature concentrates on inflammatory processes: gut-tissue models, skin models, and derivative molecules built on the same core. A 2025 review in the International Journal of Medical Sciences surveys tripeptides in wound care and tissue regeneration and identifies the class as a promising direction, with delivery and stability the main engineering questions. Human trials of KPV itself have not yet been published; the interest rests on the strength and consistency of the laboratory findings.<\/p>\n
KPV is available as a standalone vial and a nasal spray, and it is the fourth component of the KLOW blend<\/a> \u2014 the one-peptide difference we explain in KLOW vs GLOW<\/a>.<\/p>\n KPV is the three-amino-acid anti-inflammatory fragment of alpha-MSH, a naturally occurring human hormone, studied principally in gut and skin inflammation research.<\/p>\n KLOW adds KPV to the GHK-Cu, BPC-157 and TB-500 core specifically for its anti-inflammatory research profile in gut and skin tissue.<\/p>\nFrequently asked questions<\/h2>\n
What is KPV?<\/h3>\n
Why is KPV in the KLOW blend?<\/h3>\n